Organization
Department of Laboratory Medicine
5 abstracts
Abstract
Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial.Org: University of California, San Diego Medical Center, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Winship Cancer Institute of Emory University,
Abstract
Correlation of hormone receptor positive HER2-negative/MammaPrint high-2 breast cancer with triple negative breast cancer: Results from gene expression data from the ISPY2 trial.Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, Yale University School of Medicine, Bioinformatics Support Program,
Abstract
Harnessing cell-free orphan non-coding RNAs as a predictive measure of long-term survival in neoadjuvant breast cancer therapy.Org: Exai Bio Inc., UCSF Comprehensive Cancer Center, University of California, San Francisco, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV, Department of Laboratory Medicine,
Abstract
I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).Org: University of California, San Francisco, Mayo Clinic, University of Chicago Medical Center, Chicago, IL, Winship Cancer Institute of Emory University, Hunstman Cancer Institute at the University of Utah,
Abstract
Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022.Org: Duke Cancer Institute, University of California, San Francisco, University of Utah, University of California, Davis Comprehensive Cancer Center, University of Chicago Medicine,